This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
Wesana Health is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana Health is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.
Stock Performance
Wesana Health News 15 articles
- Wesana Health Announces Restructuring of Promissory Note Receivable
- Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale
- Wesana Health Announces Voting Results of AGSM
- Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery
- Wesana Health Announces Receipt of Short-Term Loan
- Wesana Announces Second Quarter 2022 Financial Results
- Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder
- Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
- Wesana Health Granted US FDA Pre-IND Meeting for SANA-013
- Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments
- Wesana Health Announces Listing on OTCQB Venture Market
- Wesana Health to Acquire Psytech in All Stock Deal
- As a Public Company, Wesana Health Aims to Solve Traumatic Brain Injury
- The World Boxing Council and Wesana Health Announce Joint Efforts to Research the Impact of Psychedelics on Traumatic Brain Injury
- Wesana Health Commences Trading on the CSE